United Community Bank Sells 110 Shares of IQVIA Holdings Inc. (NYSE:IQV)

United Community Bank trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,502 shares of the medical research company’s stock after selling 110 shares during the quarter. United Community Bank’s holdings in IQVIA were worth $688,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in IQV. Raymond James Financial Inc. bought a new stake in IQVIA during the fourth quarter valued at approximately $236,120,000. FMR LLC boosted its position in shares of IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of IQVIA during the third quarter worth $147,683,000. JPMorgan Chase & Co. boosted its position in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after acquiring an additional 583,396 shares during the last quarter. Finally, Nordea Investment Management AB boosted its position in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on IQV. Stephens began coverage on shares of IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 price target on the stock. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Stifel Nicolaus reduced their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Citigroup reduced their target price on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Finally, StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Trading Up 3.4 %

Shares of IQV opened at $191.69 on Friday. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $261.72. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm’s fifty day moving average is $197.79 and its two-hundred day moving average is $212.87. The stock has a market cap of $33.80 billion, a PE ratio of 25.56, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.